Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
Language English Country United States Media print-electronic
Document type Journal Article, Review, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't
PubMed
35181272
DOI
10.1016/j.trecan.2022.01.010
PII: S2405-8033(22)00017-6
Knihovny.cz E-resources
- Keywords
- PARP inhibitors, antiangiogenic agents, bevacizumab, immunogenic cell death, platinum derivatives, taxanes,
- MeSH
- Carcinoma, Ovarian Epithelial drug therapy MeSH
- Immunomodulation MeSH
- Humans MeSH
- Ovarian Neoplasms * drug therapy MeSH
- Antineoplastic Agents * pharmacology therapeutic use MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
- Names of Substances
- Antineoplastic Agents * MeSH
At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.
Department of Hematology and Oncology Hospital Universitario Morales Meseguer Murcia Spain
Department of Radiation Oncology Weill Cornell Medical College New York NY USA
References provided by Crossref.org
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
